APP, Second Chinese Heparin API Importer, Steps In To Fill Blood Thinner Need
This article was originally published in PharmAsia News
APP Pharmaceutical, formerly Abrexis Pharmaceutical Products, is positioning itself to be a major supplier of blood thinner to hospitals and kidney-dialysis centers. The Illinois-based firm also imports some of its active ingredient from an unnamed supplier in China, but unlike the supplier of Baxter International's troubled heparin, the APP supplier in China has been inspected by the U.S. FDA. The agency acknowledged it did not inspect Baxter's supplier because it confused the name of the company. The agency moved quickly to approve APP-related facilities to avoid a national shortage of the blood-thinner. APP says it is ready to supply U.S. needs for the drug by producing its generic version of heparin at two U.S. plants. (Click here for more - a subscription may be required
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.